BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript

BioLineRx Ltd. ( BLRX ) Q3 2025 Earnings Call November 24, 2025 8:30 AM EST Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Ella Sorani - Chief Development Officer Conference Call Participants Joseph Pantginis - H.C.

Seeking Alpha • Nov 24, 2025

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers - - Phase 1/2a clinical trial of GLIX1 expected to commence in Q1 2026 - - Management to host conference call today, November 24 th, at 8:30 am EST - TEL AVIV, Israel , Nov. 24, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended September 30, 2025, and provided a corporate update.

PRNewsWire • Nov 24, 2025

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd.

PRNewsWire • Nov 18, 2025

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not over-expressed (representing over 90% of cancers) Patent further broadens and strengthens GLIX1 patent protection until 2040, with a possible patent-term extension of up to five years TEL AVIV, Israel , Nov. 17, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent, entitled, 'Deoxy-Cytidine or Uridine Derivatives for Use in Cancer Therapies' (Pat.

PRNewsWire • Nov 17, 2025

BioLineRx Ltd. - Special Call

BioLineRx Ltd. - Special Call Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Ella Sorani - Chief Development Officer Conference Call Participants Joseph Pantginis - H.C.

Seeking Alpha • Sep 29, 2025

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only - - FDA IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 - - Glioblastoma market opportunity estimated to be in excess of $3.8 billion annually across the US and EU5 by 2030 - - BioLineRx affirms its cash runway into the first half of 2027 - - Management to host conference call today, September 29 th, at 8:30 am EDT - TEL AVIV, Israel and OSLO, Norway , Sept. 29, 2025 /PRNewswire/ -- BioLineRx Ltd.

PRNewsWire • Sep 29, 2025

BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript

BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Irina Koffler - Corporate Participant Mali Zeevi - Chief Financial Officer Philip A.

Seeking Alpha • Aug 14, 2025

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

- Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- Provides updated and extended cash runway guidance into H1 2027 -- Management to host conference call today, August 14th, at 8:30 am EDT - TEL AVIV, Israel , Aug. 14, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended June 30, 2025, and provided a corporate update.

PRNewsWire • Aug 14, 2025

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel , Aug. 7, 2025 /PRNewswire/ -- BioLineRx Ltd.

PRNewsWire • Aug 7, 2025

3 Stocks Getting Rare Double Upgrades From Analysts

Markets hate uncertainty, which has been the norm in 2025. Tariffs, interest rates, and inflation are driving analysts' expectations.

MarketBeat • Jun 6, 2025